Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-19.2	-19.03	-18.05	-14.79	-2.85	-5.72
Depreciation & Amortization	0.18	0.18	0.01	0	0	0
Share-Based Compensation	0.43	0.5	0.46	1.53	0.57	1.44
Other Operating Activities	2.61	0.27	0.24	-1.04	1.14	3.95
Operating Cash Flow	-15.98	-18.09	-17.35	-14.3	-1.13	-0.34
Capital Expenditures	-0.01	-0.01	-0.24	0	0	0
Change in Investments	14.2	11.67	-15.76	0	0	0
Investing Cash Flow	14.18	11.66	-16.01	0	0	0
Share Issuance / Repurchase	0.36	8.54	0.04	41.14	14.79	0
Debt Issued / Paid	0	0	-0.25	-0.04	0.27	-0.02
Other Financing Activities	-0.17	-0.14	-	-	-	-
Financing Cash Flow	0.19	8.41	-0.2	41.09	15.06	-0.02
Net Cash Flow	-1.6	1.98	-33.56	26.8	13.94	-0.36
Free Cash Flow	-15.99	-18.1	-17.59	-14.3	-1.13	-0.34
Free Cash Flow Margin	-8161.12%	-6947.87%	-14253.37%	-461.11%	-161.69%	-30.13%
Free Cash Flow Per Share	-2.52	-3.39	-4.17	-4.71	-0.82	-0.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).